LogicBio is a Cambridge, MA-based genome editing company focused on delivering the benefits of genetic medicine to the fight against early onset childhood diseases. Logicâs approach is based on its core proprietary technology platform, GeneRide, which enables precise, durable and site-specific integration of a therapeutic transgene without exogenous nucleases or promoters by relying on the native process of homologous recombination. Logic is initially evaluating its technology in rare liver disorders in pediatric patients where it is critical to provide treatment early in a patientâs life before irreversible disease pathology occurs. Logic has demonstrated proof of concept of its therapeutic platform in animal models for a number of diseases and is focusing on the development of its lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia, or MMA, a life-threatening disease that presents at birth.
Source
